

CURRICULUM VITAE ET STUDIORUM

PERSONAL INFORMATION

Name: Manolo D'Arcangelo

EDUCATION

Dates: 22nd October 2016 – ongoing

Name of organization: AUSL Romagna, Ospedale S. Maria delle Croci

Principal subjects/occupational skill covered:
Consultant in Medical Oncology

Dates: June 1st, 2014 – 22nd September 2016

Name of organization: Newcastle University, Newcastle upon Tyne, UK

Principal subjects/occupational skills covered:
Clinical Research Associate at Northern Institute for Cancer Research.
Phase I trials in solid tumors in the Clinical Trials Unit (Freeman Hospital, Newcastle) under the supervision of prof ER Plummer. Study of predictive biomarkers and their application in early phase drug development. Translational research.

Date: July 7th, 2014

Name of organization: General Medical Council (UK)

Title of qualification: Full registration with license to practice.

Dates: July 2012 – May 20th, 2014

Name of organization: University of Colorado, Aurora, CO, USA

Principal subjects/occupational skills covered:
Visiting fellow in Prof FR Hirsch's biomarker lab, Cancer Center, Department of Medical Oncology.
Lab research on lung cancer biology, prognostic/predictive biomarkers of thoracic malignancies.

Title of qualification: No title provided for this program.

Dates: March 21st, 2008 – April 3rd, 2012

Name of organization: University of Pisa, Italy

Principal subjects/occupational skills covered:
Specialist registrar training program in Medical Oncology.
Thesis title: "A feasibility study on cancer stem cells sensitivity assay".

Title of qualification: Specialist in Medical Oncology
Level in national qualification: 110/110 cum laude

Date: July 25th, 2007

Name of organization: University of Pisa, Italy

Principal subjects/occupational skills covered:
Board certification.

Dates: September 2000 – March 20th, 2007

Name of organization: University of Pisa, Italy

Principal subjects/occupational skills covered:

Medical school.

Thesis title: *"Pilot study of metronomic chemotherapy with cyclophosphamide, dexamethazone and celecoxib in patients with advanced ormonorefractory prostate cancer"*.

Title of qualification: M.D.

Level in national qualification: 110/110

PERSONAL SKILLS AND COMPETENCES

Languages:

ITALIAN (mother tongue)

ENGLISH

Reading skills: Excellent

Writing skills: Excellent

Verbal skills: Excellent

Technical skills:

- Competent with Microsoft and Mac technology;
- Competent with Microsoft Office;
- Outpatient and inpatient activities with special interest in thoracic cancers and early phase drug development;
- Competent with electronic medical record;
- Investigator/sub-investigator in sponsored clinical trials and non-sponsored studies;
- During thesis preparation, the candidate worked in the Pharmacology Laboratories of the University of Pisa, getting skilled with:
 - RNA and DNA extraction from blood
 - Polymorphonucleated cells isolation
 - Retro-transcriptase reactions
 - ELISA and EIA
 - RT-PCR
- During the two years in Prof Hirsch's lab, the candidate got skilled with:
 - Cell lines culture
 - In vitro sensitivity assays
 - Western Blot

- Tissue microarrays preparation
- Immunohistochemistry and in situ hybridization scoring
- miRNA evaluation

Other:

European driving license – category B
Colorado driving license

PUBLICATIONS

- 1) Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi C, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer. *Clin Cancer Res* 2009; 15(15):4954-62
- 2) Fontana A, Bocci G, Galli L, D'Arcangelo M et al. Metronomic cyclophosphamide in elderly patients with advanced, castration-resistant prostate cancer. *JAGS* 2010; 58(5): 986-8
- 3) De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M et al. Consequences of targeted treatments for second-line therapy. *Ann Oncol* 2010; Suppl 7:vii234-vii240
- 4) Califano R, D'Arcangelo M, Mok TS. Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation. *Drugs*. 2012;72Suppl 1:3-10
- 5) Califano R, D'Arcangelo M, Cappuzzo F. Maintenance therapy for advanced Non-Small-Cell Lung Cancer: is it a standard of care? *Treatment strategies in oncology – Lung Cancer*. 2011. <http://viewer.zmags.com/publication/20b83b27#/20b83b27/102>
- 6) D'Arcangelo M, Cappuzzo F. K-RAS mutations in Non-Small-Cell Lung Cancer: prognostic and predictive value. *ISRN Molecular Biology*. 2012. doi:10.5402/2012/837306
- 7) D'Arcangelo M, Cappuzzo F. Erlotinib in the first-line treatment on Non-Small-Cell Lung Cancer. *Expert Rev Anticancer Ther*. 2013;13(5):523-33
- 8) D'Arcangelo M, D'Incecco A, Cappuzzo F. Rare mutations in Non-Small Cell Lung Cancer. *Future Oncol*. 2013;9(5):699-711
- 9) D'Arcangelo M, Cappuzzo F. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. *Biologics*. 2013;7:61-8

10) D'Arcangelo M, Wynes M, Hirsch FR. The role of anaplastic lymphoma kinase (ALK) inhibitors in the treatment of advanced Non-Small Cell Lung Cancer. *Curr Opin Oncol*. 2013;25(2):121-9

11) D'Arcangelo M, Hirsch FR. Clinical and comparative utility of afatinib in non-small cell lung cancer. *Biologics*. 2014;8:183-92

12) D'Arcangelo M, Hirsch FR. Molecular diagnostics for the practicing clinician: applications in lung cancer and other tumor types. inPractice e-book: http://www.inpractice.com/System/NotFound?item=%2ftextbooks%2foncology%2fgeneral_oncology_topics%2fch53_general_diagnostics%2fchapter-pages%2fpage-1&user=extranet%5cAnonymous&site=website. Last access: December 15th, 2014.

13) D'Arcangelo M, Hirsch FR. New therapeutic strategies in lung cancer. Chapter 12: Strategies in patients with other molecular alterations. *Springer International Publishing, Switzerland* 2015. Print

14) D'Arcangelo M, Todaro M, Salvini J et al. Cancer stem cells sensitivity assay (stella) in patients with advanced lung and colorectal cancer: a feasibility study. Submitted to *PLOS One*.

ABSTRACTS

1) Fontana A, Bocci G, D'Arcangelo M et al. Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamics results. *Ann Onc* 2007; 18 (Suppl 11). Abs. D119

2) Fontana A, Bocci G, D'Arcangelo M et al. Docetaxel (D) plus Prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): phase II clinical trial with pharmacodynamic evaluation. *J Clin Oncol*. 2008; 26 (Suppl): Abs. 16084.

3) Fontana A, Bocci G, D'Arcangelo M et al. Docetaxel plus prednisone with metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC): a phase II clinical trial with pharmacodynamic evaluation. *Ann Oncol*. 2008; 19 (Suppl 8): Abs. 617P

4) Fontana A, Bocci G, D'Arcangelo M et al. Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC). *Ann Onc*. 2008; 18 (Suppl 9): Abs. E28

5) Fontana A, Bocci G, Galli L, Derosa L, Minuti G, D'Arcangelo M et al. Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC) patients (pts). *Ann Oncol*. 2009; 20 (Suppl 8): Abs.

- 6) Galli L, Fontana A, Derosa L, Minuti G, D'Arcangelo M et al. Metronomic Oral Vinorelbine (V) and Dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations. AIOM 2009, Abstract book: *Ann Oncol* 2009; 20 (Suppl 8): Abs F19
- 7) Fontana A, Galli L, Derosa L, Minuti G, D'Arcangelo M et al Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC). *Eur J Cancer*. 2009; 7 (Suppl 2): Abs.7036
- 8) D'Arcangelo M and Cappuzzo F. Maintenance therapy in Non-Small-Cell Lung Cancer. Abstract book of the Third Conference of Gruppo Oncologico Chirurgico Cooperativo Italiano.
- 9) D'Arcangelo M and Cappuzzo F. An International perspective on NSCLC treatment. Abstract book of the congress *Oncology Update 2012*.
- 10) D'Arcangelo M and Cappuzzo F. Maintenance therapy in NSCLC. Abstract book of the congress *Oncology Update 2012*.
- 11) D'Arcangelo M, Volpe S, Todaro M, Stassi G, Salvini J, D'Incecco A, Landi L, Minuti G, Lani E and Cappuzzo F. Cancer Stem Cells (CSCs) Sensitivity Assay for Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients. Abstract book of the Third European Lung Cancer Conference 2012. Abs. 104P
- 12) D'Arcangelo M, Todaro M, Benfante A, Colorito ML, Volpe S, Salvini J, Landi L, D'Incecco A, Lani E, Stassi G and Cappuzzo F. Cancer Stem Cells sensitivity assay as a new strategy for treatment of metastatic Non-Small-Cell Lung Cancer. Poster presentation at the 3rd International Conference on Thoracic Oncology 2012.
- 13) Kowanetz M, Shames DS, Koeppen H, Xiao Y, Behrens C, Desai R, Fu L, Chappay C, Mokatrini A, Kadel EE, Do A, Brustugun OT, D'Arcangelo M et al. Prevalence and prognostic association of PD-L1 protein and immune gene expression in NSCLC. Abstract book of the 15th World Conference on Lung Cancer 2013. Abs. MO19.10
- 14) Shames DS, Xiao Y, Choi YJ, Behrens C, Solis LM, Peale F, Koeppen H, Firestein R, Stern H, Wang Y, Kowanetz M, Lackner M, Mocci S, Yauch RL, Hampton G, Boyle T, D'Arcangelo M et al. The High Incidence of Overlap between Actionable Biomarkers in NSCLC: Potential Impact on Future Clinical Trial Design. Abstract book of the 15th World Conference on Lung Cancer 2013. Abs. P2.06-005
- 15) D'Arcangelo M, Brustugun OT, Xiao Y, et al. Prevalence and prognostic significance of sodium-dependent phosphate transporter 2B (NaPi2b) protein expression in non-small cell lung cancer (NSCLC). *Ann Oncol* 2014; 25 (Suppl 4): iv58-iv84. Abs. 194P
- 16) D'Arcangelo M, Ekman S, Dougall W et al. Protein expression for receptor

activator of NF κ B (RANK) and its ligand (RANKL) in non-small cell lung cancer (NSCLC). *Eur J Cancer* 2014; 50 (Suppl 6): 114. Abs. 353

A handwritten signature in black ink, appearing to be 'Leo D. Leo'.

20-DEC-2017